Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study

키워드

참고문헌 (56)

1. Sawada K, "Impact of subjective vs. objective remission status on subjective cognitive impairments in depression", J Affect Disord, 246, pp.99~104 (2019)
2. 김재민, "Development of a Korean Version of the Perceived Deficits Questionnaire-Depression for Patients with Major Depressive Disorder", Clinical Psychopharmacology and Neuroscience, 14(1), pp.26~32 (2016), 대한정신약물학회
3. Zlatar ZZ, "Subjective cognitive decline, objective cognition, and depression in older Hispanics screened for memory impairment", J Alzheimers Dis, 63, pp.949~956 (2018)
4. Hill NL, "Subjective cognitive impairment and affective symptoms: a systematic review", Gerontologist, 56, pp.e109~e127 (2016)
5. Abdulrab K, "Subjective memory impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria", Eur Psychiatry, 23, pp.321~330 (2008)
6. Jessen F, "A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease", Alzheimers Dement, 10, pp.844~852 (2014)
7. Dufouil C, "Subjective cognitive complaints and cognitive decline: consequence or predictor? The epidemiology of vascular aging study", J Am Geriatr Soc, 53, pp.616~621 (2005)
8. Geerlings MI, "Association between memory complaints and incident Alzheimer’s disease in elderly people with normal baseline cognition", Am J Psychiatry, 156, pp.531~537 (1999)
9. van Oijen M, "Subjective memory complaints, education, and risk of Alzheimer’s disease", Alzheimers Dement, 3, pp.92~97 (2007)
10. Jorm AF, "Memory complaints as a precursor of memory impairment in older people: a longitudinal analysis over 7-8 years", Psychol Med, 31, pp.441~449 (2001)
11. Buckley R, "Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age", Int Psychogeriatr, 25, pp.1307~1315 (2013)
12. van Harten AC, "Subjective cognitive decline and risk of MCI: the Mayo Clinic Study of Aging", Neurology, 91, pp.e300~e312 (2018)
13. Amieva H, "Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms", Ann Neurol, 64, pp.492~498 (2008)
14. Afridi MI, "Cognitive disturbance comparison among drug-naïve depressed cases and healthy controls", J Coll Physicians Surg Pak, 21, pp.351~355 (2011)
15. American Psychiatric Association, "Diagnostic and statistical manual of mental disorder" (2013), American Psychiatric Association
16. Pandina GJ, "Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial", J Affect Disord, 118, pp.139~146 (2009)
17. Pandina GJ, "Psychometric evaluation of a patient-rated most troubling symptom scale for depression: findings from a secondary analysis of a clinical trial", Int Clin Psychopharmacol, 25, pp.51~59 (2010)
18. Potvin S, "Self-evaluation and objective assessment of cognition in major depression and attention deficit disorder: implications for clinical practice", Compr Psychiatry, 70, pp.53~64 (2016)
19. Sumiyoshi T, "Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder:cross-sectional analysis of baseline data from PERFORM-J", J Affect Disord, 258, pp.172~178 (2019)
20. Manit S, "Cognitive dysfunction in Asian patients with depression (CogDAD): a cross-sectional study", Clin Pract Epidemiol Ment Health, 13, pp.185~199 (2017)
21. Buist-Bouwman MA, "Mediators of the association between depression and role functioning", Acta Psychiatr Scand, 118, pp.451~458 (2008)
22. Ott CV, "Screening for cognitive dysfunction in unipolar depression: validation and evaluation of objective and subjective tools", J Affect Disord, 190, pp.607~615 (2016)
23. Allott K, "Subjective cognitive functioning in relation to changes in levels of depression and anxiety in youth over 3 months of treatment", BJPsych Open, 6, pp.e84~ (2020)
24. Gelenberg AJ, "American Psychiatric Association practice guidelines for the treatment of patients with major depressive disorder", Am J Psychiatry, 167, pp.9~118 (2010)
25. Pilling S, "Depression in adults, including those with a chronic physical health problem: summary of NICE guidance", BMJ, 339, pp.b4108~ (2009)
26. Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT)2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)
27. Mahableshwarkar AR, "A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder", Neuropsychopharmacology, 40, pp.2025~2037 (2015)
28. Katona C, "A randomized, double-blind, placebocontrolled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder", Int Clin Psychopharmacol, 27, pp.215~223 (2012)
29. Rosenblat JD, "The cognitive effects of antidepressants in major depressive disorder: a systematic review and metaanalysis of randomized clinical trials", Int J Neuropsychopharmacol, 19, pp.pyv082~ (2016)
30. Reddy S, "The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial", J Psychopharmacol, 30, pp.559~567 (2016)
31. Herrera-Guzmán I, "Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder", J Psychiatr Res, 43, pp.855~863 (2009)
32. Lam RW, "Psychometric validation of the perceived deficits questionnaire-depression (PDQ-D) instrument in US and UK respondents with major depressive disorder", Neuropsychiatr Dis Treat, 14, pp.2861~2877 (2018)
33. Iverson GL, "Rapid screening for perceived cognitive impairment in major depressive disorder", Ann Clin Psychiatry, 25, pp.135~140 (2013)
34. Wade AG, "Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in major depressive disorder (MDD):an open-label, pilot study", BMC Psychiatry, 11, pp.42~ (2011)
35. Li G, "Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: a pooled analysis of 4 Chinese clinical trials", Medicine (Baltimore), 96, pp.e8142~ (2017)
36. Liebowitz MR, "A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg", day in adult outpatients with major depressive disorder, 2013, pp.13, 94~
37. DeMartinis NA, "A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder", J Clin Psychiatry, 68, pp.677~688 (2007)
38. McIntyre RS, "A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults", Int J Neuropsychopharmacol, 17, pp.1557~1567 (2014)
39. Cipriani A, "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder:a systematic review and network meta-analysis", Lancet, 391, pp.1357~1366 (2018)
40. Garcia-Ptacek S, "Subjective cognitive impairment: towards early identification of Alzheimer disease", Neurologia, 31, pp.562~571 (2016)
41. Jorge RE, "Escitalopram and enhancement of cognitive recovery following stroke", Arch Gen Psychiatry, 67, pp.187~196 (2010)
42. Savaskan E, "Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients", Int J Neuropsychopharmacol, 11, pp.381~388 (2008)
43. "Brintellix European Public Assessment Reports"[URL]
44. Lam RW, "The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder", J Affect Disord, 203, pp.55~61 (2016)
45. Ramos BP, "Adrenergic pharmacology and cognition: focus on the prefrontal cortex", Pharmacol Ther, 113, pp.523~536 (2007)
46. Cowen P, "The role of serotonin in cognitive function:evidence from recent studies and implications for understanding depression", J Psychopharmacol, 27, pp.575~583 (2013)
47. Stahl SM, "Stahl’s essential psychopharmacology: neuroscientific basis and practical applications" (2013), Cambridge University Press
48. Drevets WC, "Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism", Eur Neuropsychopharmacol, 12, pp.527~544 (2002)
49. Moret C, "The importance of norepinephrine in depression", Neuropsychiatr Dis Treat, 7, pp.9~13 (2011)
50. Stahl SM, "Symptoms and circuits, part 1: major depressive disorder", J Clin Psychiatry, 64, pp.1282~1283 (2003)
51. Dell’Osso B, "Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice", Neuropsychiatr Dis Treat, 11, pp.1885~1909 (2015)
52. Lader M, "Benzodiazepines revisited--will we ever learn?", Addiction, 106, pp.2086~2109 (2011)
53. Baldwin DS, "Benzodiazepines: risks and benefits. A reconsideration", J Psychopharmacol, 27, pp.967~971 (2013)
54. Tannenbaum C, "A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs", Drugs Aging, 29, pp.639~658 (2012)
55. Furlan AD, "2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group", Spine (Phila Pa 1976), 34, pp.1929~1941 (2009)
56. Wagner S, "A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment", Acta Psychiatr Scand, 125, pp.281~292 (2012)

관련 논문AI추천